Decision to fine liothyronine supplier millions ofpounds for price hikes upheld at tribunal

摘要

The Competition Appeal Tribunal has upheld a decision (https://www.catribunal.org.uk/sites/cat/fi les/2023-08/Liothyronine%20%281419%3B1421- 1422%29%20-%20Judgment%20%208%20Aug%202023.pdf) by the Competition andMarkets Authority (CMA) to fine drug company Advanz Pharma, and two former owners, forincreasing the price of liothyronine by over 1,000%.